ABVC BioPharma Receives US Patent for ADHD Treatment Using PDC-1421
ABVC BioPharma, a clinical-stage biopharmaceutical company, has announced the receipt of a US patent for the use of PDC-1421, a Radix Polygala extract, in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The patent, which grants ABVC the exclusive rights to use, offer, or sell PDC-1421 in the United States until 2040, is a significant milestone for the company.
According to ABVC CEO Dr. Uttam Patil, the company is also working towards expanding its patent coverage globally, with applications pending in the European Union, China, Japan, and other countries. The patent application, titled “Polygala Extract for the Treatment of ADHD,” is based on the oral administration of PDC-1421 as a capsule for treating ADHD. The dosage is three times a day for eight weeks, with each dose containing 380-760 mg of the botanical extract.
ABV-1505, the company’s asset for treating ADHD, has completed Phase IIa clinical studies and is currently undergoing Phase IIb trials. The interim report is expected to be released by the end of the year. The global ADHD treatment market is projected to reach $32.14 billion by 2030, with a CAGR of 7.1% over the forecast period, according to a Polaris market research report.
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device under development. The company utilizes in-licensed technology from renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. Its network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center.
The company also plans to conduct global clinical trials for its medical device, Vitargus®, through Phase III. ABVC BioPharma cautions that forward-looking statements, such as those in this press release, are subject to various known and unknown risks and uncertainties, which may affect the realization of these statements. These risks and uncertainties include difficulties in obtaining financing, changes in competition, and difficulties in securing regulatory approval for clinical trials and product marketing.
ABVC BioPharma’s receipt of a US patent for its ADHD treatment using PDC-1421 is a significant achievement for the company.
